Correction to: Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial

被引：0
|
作者：
Bee Kim Tan
Siew Siang Chua
Li-Chia Chen
Kian Meng Chang
Sharmini Balashanker
Ping Chong Bee
机构：
[1] Jalan Universiti,Department of Medicine, Faculty of Medicine, University of Malaya
[2] Taylor’s University,School of Pharmacy, Faculty of Health and Medical Sciences
[3] University of Manchester,Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health
[4] Manchester Academic Health Science Centre,Department of Hematology
[5] Ampang Hospital,School of Pharmacy
[6] Ministry of Health Malaysia,undefined
[7] University of Nottingham Malaysia Campus,undefined
来源：
Supportive Care in Cancer | 2020年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Revised Funding Information.
引用
收藏
页码：3249 / 3249
相关论文
共 50 条
  • [41] Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data
    Irvine, David A.
    Heaney, Nicholas B.
    Holyclake, Tessa L.
    BLOOD REVIEWS, 2010, 24 (01) : 1 - 9
  • [42] Medication Adherence in Patients with Chronic Myelogenous Leukemia Using Tyrosine-Kinase Inhibitors: A Retrospective Analysis
    Esposti, Luca Degli
    Saragoni, Stefania
    Buda, Stefano
    Calandriello, Mario
    BLOOD, 2014, 124 (21)
  • [43] Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations
    Xue, Mingming
    Cheng, Juan
    Zhao, Jiangyun
    Zhang, Shuling
    Jian, Jinli
    Qiao, Yanhong
    Liu, Bei
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 (01) : 94 - 101
  • [44] Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response
    Santoleri, Fiorenzo
    Lasala, Ruggero
    Ranucci, Elena
    La Barba, Gaetano
    Di Lorenzo, Roberto
    Vetro, Antonio
    Di Bartolomeo, Paolo
    Costantini, Alberto
    ACTA HAEMATOLOGICA, 2016, 136 (01) : 45 - 51
  • [45] LONG TERM RESULTS WITH TYROSINE KINASE INHIBITORS BCR-ABL IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE
    Nunnz Yizel, Paz
    Gabriela, Silva Carreras F.
    Victoria, Vaitsekhovich
    Cecile, Mba
    Navascues Javier, Cornago
    Juan Luis, Steegmann Olmedillas
    HAEMATOLOGICA, 2016, 101 : 176 - 176
  • [46] Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
    Trivedi, Digisha
    Amin, Shahla
    Zhu, Ling
    Joo, Sam
    Kawabata, Hugh
    Darkow, Theodore
    Hebden, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis
    Fachi, Mariana M.
    Tonin, Fernanda S.
    Leonart, Leticia P.
    Aguiar, Karina S.
    Lenzi, Luana
    Figueiredo, Bonald C.
    Fernandez-Llimos, Fernando
    Pontarolo, Roberto
    EUROPEAN JOURNAL OF CANCER, 2018, 104 : 9 - 20
  • [48] Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia - Cluster randomised controlled trial
    Gray, R
    Wykes, T
    Edmonds, M
    Leese, M
    Gournay, K
    BRITISH JOURNAL OF PSYCHIATRY, 2004, 185 : 157 - 162
  • [49] Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors
    Sasaki, Koji
    Jabbour, Elias
    Issa, Ghayas C.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Wierda, William G.
    Yilmaz, Musa
    DiNardo, Courtney D.
    Skinner, Jeffrey
    Khouri, Maria
    Pemmaraju, Naveen
    Nasnas, Patrice
    Pierce, Sherry A.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
  • [50] Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Jung, Y. S.
    Kim, M.
    Lee, J. H.
    Kim, D. W.
    Park, H. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (02) : 456 - 458
12345